_id
6919e4713c536f8df2318097
Ticker
AREC.LSE
Name
Arecor Therapeutics PLC
Exchange
LSE
Address
Chesterford Research Park, Little Chesterford, United Kingdom, CB10 1XL
Country
UK
Sector
Healthcare
Industry
Biotechnology
Currency
GBX
Website
https://arecor.com
Description
Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes; and specialty hospital products. In addition, the company is developing AT247, an ultra-rapid acting insulin, which is in Phase 1 for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product; and Medtronic plc to develop a novel thermostable insulin for implantable pump delivery. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Last Close
805000
Volume
168650
Current Price
90
Change
-0.43478260869564517
Last Updated
2025-12-29T14:59:36.526Z
Image
https://logo.clearbit.com/arecor.com
Ipo Date
-
Market Cap
30205282
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4
Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
2003000
Cost Of Revenue
1675000
Gross Profit
328000
Operating Expenses
3391000
Operating Income
-3063000
Interest Expense
8000
Pretax Income
-2542000
Net Income
-2508000
Eps
-0.0664254708732918
Dividends Per Share
-
Shares Outstanding
37756601
Income Tax Expense
-34000
EBITDA
-2421000
Operating Margin
-152.9206190713929
Total Other Income Expense Net
521000
Cash
1867000
Short Term Investments
19000
Receivables
2774000
Inventories
112000
Total Current Assets
4772000
Property Plant Equipment
396000
Total Assets
5250000
Payables
2169000
Short Term Debt
114000
Long Term Debt
-
Total Liabilities
2394000
Equity
2856000
Bs_currency_symbol
GBP
Depreciation
113000
Change In Working Capital
1168000
Cash From Operations
-1143000
Capital Expenditures
98000
Cash From Investing
11000
Cash From Financing
-68000
Net Change In Cash
-1372000
Cf_currency_symbol
-
PE
-
PB
1189.8088550420168
ROE
-87.81512605042016
ROA
-47.77142857142857
FCF
-1241000
Fcf Percent
-0.6195706440339491
Piotroski FScore
1
Health Score
23
Deep Value Investing Score
2
Defensive Investing Score
6.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.3
Garp Investing Score
2
Growth Investing Score
1
Momentum Investing Score
2
Net Net Investing Score
2.5
Quality Investing Score
2
Value Investing Score
2.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
2003000
Quarters > 0 > income Statement > cost Of Revenue
1675000
Quarters > 0 > income Statement > gross Profit
328000
Quarters > 0 > income Statement > operating Expenses
3391000
Quarters > 0 > income Statement > operating Income
-3063000
Quarters > 0 > income Statement > interest Expense
8000
Quarters > 0 > income Statement > pretax Income
-2542000
Quarters > 0 > income Statement > net Income
-2508000
Quarters > 0 > income Statement > eps
-0.0664254708732918
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
37756601
Quarters > 0 > income Statement > income Tax Expense
-34000
Quarters > 0 > income Statement > EBITDA
-2421000
Quarters > 0 > income Statement > operating Margin
-152.9206190713929
Quarters > 0 > income Statement > total Other Income Expense Net
521000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
1867000
Quarters > 0 > balance Sheet > short Term Investments
19000
Quarters > 0 > balance Sheet > receivables
2774000
Quarters > 0 > balance Sheet > inventories
112000
Quarters > 0 > balance Sheet > total Current Assets
4772000
Quarters > 0 > balance Sheet > property Plant Equipment
396000
Quarters > 0 > balance Sheet > total Assets
5250000
Quarters > 0 > balance Sheet > payables
2169000
Quarters > 0 > balance Sheet > short Term Debt
114000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
2394000
Quarters > 0 > balance Sheet > equity
2856000
Quarters > 0 > balance Sheet > currency_symbol
GBP
Quarters > 0 > cash Flow > net Income
-2508000
Quarters > 0 > cash Flow > depreciation
113000
Quarters > 0 > cash Flow > change In Working Capital
1168000
Quarters > 0 > cash Flow > cash From Operations
-1143000
Quarters > 0 > cash Flow > capital Expenditures
98000
Quarters > 0 > cash Flow > cash From Investing
11000
Quarters > 0 > cash Flow > cash From Financing
-68000
Quarters > 0 > cash Flow > net Change In Cash
-1372000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.0664254708732918
Quarters > 0 > ratios > PB
1189.8088550420168
Quarters > 0 > ratios > ROE
-87.81512605042016
Quarters > 0 > ratios > ROA
-47.77142857142857
Quarters > 0 > ratios > FCF
-1241000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-0.6195706440339491
Quarters > 0 > health Score
23
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
3058000
Quarters > 1 > income Statement > cost Of Revenue
3510000
Quarters > 1 > income Statement > gross Profit
-672000
Quarters > 1 > income Statement > operating Expenses
5411000
Quarters > 1 > income Statement > operating Income
-2803000
Quarters > 1 > income Statement > interest Expense
10000
Quarters > 1 > income Statement > pretax Income
-5827000
Quarters > 1 > income Statement > net Income
-5596000
Quarters > 1 > income Statement > eps
-0.14820000029661187
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
37759784
Quarters > 1 > income Statement > income Tax Expense
-231000
Quarters > 1 > income Statement > EBITDA
-5597000
Quarters > 1 > income Statement > operating Margin
-91.66121648136037
Quarters > 1 > income Statement > total Other Income Expense Net
-3024000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
3239000
Quarters > 1 > balance Sheet > short Term Investments
18000
Quarters > 1 > balance Sheet > receivables
2874000
Quarters > 1 > balance Sheet > inventories
478000
Quarters > 1 > balance Sheet > total Current Assets
8234000
Quarters > 1 > balance Sheet > property Plant Equipment
400000
Quarters > 1 > balance Sheet > total Assets
8722000
Quarters > 1 > balance Sheet > payables
838000
Quarters > 1 > balance Sheet > short Term Debt
242000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
3373000
Quarters > 1 > balance Sheet > equity
5349000
Quarters > 1 > balance Sheet > currency_symbol
GBP
Quarters > 1 > cash Flow > net Income
-5596000
Quarters > 1 > cash Flow > depreciation
220000
Quarters > 1 > cash Flow > change In Working Capital
-2818000
Quarters > 1 > cash Flow > cash From Operations
-4946000
Quarters > 1 > cash Flow > capital Expenditures
8000
Quarters > 1 > cash Flow > cash From Investing
-10000
Quarters > 1 > cash Flow > cash From Financing
5713000
Quarters > 1 > cash Flow > net Change In Cash
710000
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.14820000029661187
Quarters > 1 > ratios > PB
635.3300729108245
Quarters > 1 > ratios > ROE
-104.6176855487007
Quarters > 1 > ratios > ROA
-64.15959642283879
Quarters > 1 > ratios > FCF
-4954000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-1.620013080444735
Quarters > 1 > health Score
23
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
1995000
Quarters > 2 > income Statement > cost Of Revenue
-220000
Quarters > 2 > income Statement > gross Profit
2215000
Quarters > 2 > income Statement > operating Expenses
5141000
Quarters > 2 > income Statement > operating Income
-7894000
Quarters > 2 > income Statement > interest Expense
12000
Quarters > 2 > income Statement > pretax Income
-4791000
Quarters > 2 > income Statement > net Income
-4640000
Quarters > 2 > income Statement > eps
-0.1515003794366184
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
30626986
Quarters > 2 > income Statement > income Tax Expense
-151000
Quarters > 2 > income Statement > EBITDA
-4553000
Quarters > 2 > income Statement > operating Margin
-395.6892230576441
Quarters > 2 > income Statement > total Other Income Expense Net
3103000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
2529000
Quarters > 2 > balance Sheet > short Term Investments
16000
Quarters > 2 > balance Sheet > receivables
1852000
Quarters > 2 > balance Sheet > inventories
446000
Quarters > 2 > balance Sheet > total Current Assets
6376000
Quarters > 2 > balance Sheet > property Plant Equipment
694000
Quarters > 2 > balance Sheet > total Assets
10366000
Quarters > 2 > balance Sheet > payables
2268000
Quarters > 2 > balance Sheet > short Term Debt
222000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
5288000
Quarters > 2 > balance Sheet > equity
5078000
Quarters > 2 > balance Sheet > currency_symbol
GBP
Quarters > 2 > cash Flow > net Income
-4640000
Quarters > 2 > cash Flow > depreciation
452000
Quarters > 2 > cash Flow > change In Working Capital
291000
Quarters > 2 > cash Flow > cash From Operations
-4163000
Quarters > 2 > cash Flow > capital Expenditures
15000
Quarters > 2 > cash Flow > cash From Investing
1683000
Quarters > 2 > cash Flow > cash From Financing
-65000
Quarters > 2 > cash Flow > net Change In Cash
-2564000
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.1515003794366184
Quarters > 2 > ratios > PB
542.8177904686885
Quarters > 2 > ratios > ROE
-91.37455691217015
Quarters > 2 > ratios > ROA
-44.76172101099749
Quarters > 2 > ratios > FCF
-4178000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-2.094235588972431
Quarters > 2 > health Score
17
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
997500
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
997500
Quarters > 3 > income Statement > operating Expenses
3414500
Quarters > 3 > income Statement > operating Income
-2417000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-2395500
Quarters > 3 > income Statement > net Income
-2320000
Quarters > 3 > income Statement > eps
-0.0757501897183092
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
30626986
Quarters > 3 > income Statement > income Tax Expense
75500
Quarters > 3 > income Statement > EBITDA
-2304000
Quarters > 3 > income Statement > operating Margin
-242.30576441102758
Quarters > 3 > income Statement > total Other Income Expense Net
21500
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
2529000
Quarters > 3 > balance Sheet > short Term Investments
16000
Quarters > 3 > balance Sheet > receivables
1624000
Quarters > 3 > balance Sheet > inventories
446000
Quarters > 3 > balance Sheet > total Current Assets
6376000
Quarters > 3 > balance Sheet > property Plant Equipment
694000
Quarters > 3 > balance Sheet > total Assets
10366000
Quarters > 3 > balance Sheet > payables
2268000
Quarters > 3 > balance Sheet > short Term Debt
111000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
5288000
Quarters > 3 > balance Sheet > equity
5078000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-2320000
Quarters > 3 > cash Flow > depreciation
113000
Quarters > 3 > cash Flow > change In Working Capital
321500
Quarters > 3 > cash Flow > cash From Operations
-2081500
Quarters > 3 > cash Flow > capital Expenditures
7500
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-32500
Quarters > 3 > cash Flow > net Change In Cash
-1282000
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.0757501897183092
Quarters > 3 > ratios > PB
542.8177904686885
Quarters > 3 > ratios > ROE
-45.687278456085075
Quarters > 3 > ratios > ROA
-22.380860505498745
Quarters > 3 > ratios > FCF
-2089000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-2.094235588972431
Quarters > 3 > health Score
17
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
5053000
Annuals > 0 > income Statement > cost Of Revenue
3510000
Annuals > 0 > income Statement > gross Profit
1543000
Annuals > 0 > income Statement > operating Expenses
12240000
Annuals > 0 > income Statement > operating Income
-10697000
Annuals > 0 > income Statement > interest Expense
22000
Annuals > 0 > income Statement > pretax Income
-10618000
Annuals > 0 > income Statement > net Income
-10236000
Annuals > 0 > income Statement > eps
-0.3061026204549398
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
33439766
Annuals > 0 > income Statement > income Tax Expense
-382000
Annuals > 0 > income Statement > EBITDA
-10150000
Annuals > 0 > income Statement > operating Margin
-211.69602216505046
Annuals > 0 > income Statement > total Other Income Expense Net
79000
Annuals > 0 > income Statement > currency_symbol
GBP
Annuals > 0 > balance Sheet > cash
3239000
Annuals > 0 > balance Sheet > short Term Investments
18000
Annuals > 0 > balance Sheet > receivables
2874000
Annuals > 0 > balance Sheet > inventories
478000
Annuals > 0 > balance Sheet > total Current Assets
8234000
Annuals > 0 > balance Sheet > property Plant Equipment
400000
Annuals > 0 > balance Sheet > total Assets
8722000
Annuals > 0 > balance Sheet > payables
838000
Annuals > 0 > balance Sheet > short Term Debt
242000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
3373000
Annuals > 0 > balance Sheet > equity
5349000
Annuals > 0 > balance Sheet > currency_symbol
GBP
Annuals > 0 > cash Flow > net Income
-10618000
Annuals > 0 > cash Flow > depreciation
446000
Annuals > 0 > cash Flow > change In Working Capital
-2527000
Annuals > 0 > cash Flow > cash From Operations
-9155000
Annuals > 0 > cash Flow > capital Expenditures
23000
Annuals > 0 > cash Flow > cash From Investing
1719000
Annuals > 0 > cash Flow > cash From Financing
5648000
Annuals > 0 > cash Flow > net Change In Cash
-1854000
Annuals > 0 > cash Flow > currency_symbol
GBP
Annuals > 0 > ratios > PE
-0.3061026204549398
Annuals > 0 > ratios > PB
503.2531618994205
Annuals > 0 > ratios > ROE
-191.36287156477846
Annuals > 0 > ratios > ROA
-117.3584040357716
Annuals > 0 > ratios > FCF
-9178000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-1.8163467247179894
Annuals > 0 > health Score
23
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
4573000
Annuals > 1 > income Statement > cost Of Revenue
3322000
Annuals > 1 > income Statement > gross Profit
4573000
Annuals > 1 > income Statement > operating Expenses
13748000
Annuals > 1 > income Statement > operating Income
-9175000
Annuals > 1 > income Statement > interest Expense
15000
Annuals > 1 > income Statement > pretax Income
-8901000
Annuals > 1 > income Statement > net Income
-8554000
Annuals > 1 > income Statement > eps
-0.27933597586777514
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
30622622
Annuals > 1 > income Statement > income Tax Expense
-347000
Annuals > 1 > income Statement > EBITDA
-8390000
Annuals > 1 > income Statement > operating Margin
-200.63415700852835
Annuals > 1 > income Statement > total Other Income Expense Net
274000
Annuals > 1 > income Statement > currency_symbol
GBP
Annuals > 1 > balance Sheet > cash
5093000
Annuals > 1 > balance Sheet > short Term Investments
1659000
Annuals > 1 > balance Sheet > receivables
2866000
Annuals > 1 > balance Sheet > inventories
771000
Annuals > 1 > balance Sheet > total Current Assets
11170000
Annuals > 1 > balance Sheet > property Plant Equipment
834000
Annuals > 1 > balance Sheet > total Assets
15377000
Annuals > 1 > balance Sheet > payables
2246000
Annuals > 1 > balance Sheet > short Term Debt
236000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
5850000
Annuals > 1 > balance Sheet > equity
9527000
Annuals > 1 > balance Sheet > currency_symbol
GBP
Annuals > 1 > cash Flow > net Income
-8554000
Annuals > 1 > cash Flow > depreciation
496000
Annuals > 1 > cash Flow > change In Working Capital
891000
Annuals > 1 > cash Flow > cash From Operations
-5841000
Annuals > 1 > cash Flow > capital Expenditures
151000
Annuals > 1 > cash Flow > cash From Investing
6520000
Annuals > 1 > cash Flow > cash From Financing
-180000
Annuals > 1 > cash Flow > net Change In Cash
328000
Annuals > 1 > cash Flow > currency_symbol
GBP
Annuals > 1 > ratios > PE
-0.27933597586777514
Annuals > 1 > ratios > PB
258.751030859662
Annuals > 1 > ratios > ROE
-89.78692138133725
Annuals > 1 > ratios > ROA
-55.62853612538207
Annuals > 1 > ratios > FCF
-5992000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-1.310299584517822
Annuals > 1 > health Score
22
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
2403000
Annuals > 2 > income Statement > cost Of Revenue
341000
Annuals > 2 > income Statement > gross Profit
2403000
Annuals > 2 > income Statement > operating Expenses
12915000
Annuals > 2 > income Statement > operating Income
-11660000
Annuals > 2 > income Statement > interest Expense
21000
Annuals > 2 > income Statement > pretax Income
-10542000
Annuals > 2 > income Statement > net Income
-9260000
Annuals > 2 > income Statement > eps
-0.32001561510318877
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
28936088
Annuals > 2 > income Statement > income Tax Expense
-1282000
Annuals > 2 > income Statement > EBITDA
-10062000
Annuals > 2 > income Statement > operating Margin
-485.22679983354135
Annuals > 2 > income Statement > total Other Income Expense Net
88000
Annuals > 2 > income Statement > currency_symbol
GBP
Annuals > 2 > balance Sheet > cash
4765000
Annuals > 2 > balance Sheet > short Term Investments
8041000
Annuals > 2 > balance Sheet > receivables
664000
Annuals > 2 > balance Sheet > inventories
1131000
Annuals > 2 > balance Sheet > total Current Assets
17477000
Annuals > 2 > balance Sheet > property Plant Equipment
838000
Annuals > 2 > balance Sheet > total Assets
21765000
Annuals > 2 > balance Sheet > payables
1709000
Annuals > 2 > balance Sheet > short Term Debt
404000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
4310000
Annuals > 2 > balance Sheet > equity
17455000
Annuals > 2 > balance Sheet > currency_symbol
GBP
Annuals > 2 > cash Flow > net Income
-10542000
Annuals > 2 > cash Flow > depreciation
341000
Annuals > 2 > cash Flow > change In Working Capital
-1659000
Annuals > 2 > cash Flow > cash From Operations
-10780000
Annuals > 2 > cash Flow > capital Expenditures
345000
Annuals > 2 > cash Flow > cash From Investing
-7993000
Annuals > 2 > cash Flow > cash From Financing
5160000
Annuals > 2 > cash Flow > net Change In Cash
-13551000
Annuals > 2 > cash Flow > currency_symbol
GBP
Annuals > 2 > ratios > PE
-0.32001561510318877
Annuals > 2 > ratios > PB
133.44915978229733
Annuals > 2 > ratios > ROE
-53.0507018046405
Annuals > 2 > ratios > ROA
-42.545371008499885
Annuals > 2 > ratios > FCF
-11125000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-4.62962962962963
Annuals > 2 > health Score
26
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
1158000
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
1158000
Annuals > 3 > income Statement > operating Expenses
7135000
Annuals > 3 > income Statement > operating Income
-5977000
Annuals > 3 > income Statement > interest Expense
507000
Annuals > 3 > income Statement > pretax Income
-6945000
Annuals > 3 > income Statement > net Income
-6169000
Annuals > 3 > income Statement > eps
-0.26782822524835653
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
23033420
Annuals > 3 > income Statement > income Tax Expense
-776000
Annuals > 3 > income Statement > EBITDA
-6267000
Annuals > 3 > income Statement > operating Margin
-516.1485319516407
Annuals > 3 > income Statement > total Other Income Expense Net
-506000
Annuals > 3 > income Statement > currency_symbol
GBP
Annuals > 3 > balance Sheet > cash
18316000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
795000
Annuals > 3 > balance Sheet > inventories
0
Annuals > 3 > balance Sheet > total Current Assets
20515000
Annuals > 3 > balance Sheet > property Plant Equipment
328000
Annuals > 3 > balance Sheet > total Assets
20921000
Annuals > 3 > balance Sheet > payables
518000
Annuals > 3 > balance Sheet > short Term Debt
252000
Annuals > 3 > balance Sheet > long Term Debt
0
Annuals > 3 > balance Sheet > total Liabilities
2372000
Annuals > 3 > balance Sheet > equity
18549000
Annuals > 3 > balance Sheet > currency_symbol
GBP
Annuals > 3 > cash Flow > net Income
-6945000
Annuals > 3 > cash Flow > depreciation
171000
Annuals > 3 > cash Flow > change In Working Capital
-419000
Annuals > 3 > cash Flow > cash From Operations
-5450000
Annuals > 3 > cash Flow > capital Expenditures
69000
Annuals > 3 > cash Flow > cash From Investing
-68000
Annuals > 3 > cash Flow > cash From Financing
20931000
Annuals > 3 > cash Flow > net Change In Cash
15418000
Annuals > 3 > cash Flow > currency_symbol
GBP
Annuals > 3 > ratios > PE
-0.26782822524835653
Annuals > 3 > ratios > PB
99.96173971642676
Annuals > 3 > ratios > ROE
-33.25785756644563
Annuals > 3 > ratios > ROA
-29.487118206586683
Annuals > 3 > ratios > FCF
-5519000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-4.765975820379966
Annuals > 3 > health Score
26
Valuation > metrics > PE
-0.0664254708732918
Valuation > metrics > PB
1189.8088550420168
Valuation > final Score
20
Valuation > verdict
39560.3% Overvalued
Profitability > metrics > ROE
-87.81512605042016
Profitability > metrics > ROA
-52.55658005029338
Profitability > metrics > Net Margin
-1.2521218172740889
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.8382352941176471
Risk > metrics > Interest Coverage
-382.875
Risk > final Score
-1483
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.0902321506789314
Liquidity > metrics > Quick Ratio
2.0411738939991237
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
20
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-1073
Prev Risks > 1
-2601
Prev Risks > 2
-76
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:59:48.292Z
Earnings History > 0 > period
2025-06-30
Earnings History > 0 > report Date
2025-09-25
Earnings History > 0 > date
2025-06-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.07
Earnings History > 0 > eps Estimate
0
Earnings History > 0 > eps Difference
-0.07
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-03-31
Earnings History > 1 > report Date
2025-05-06
Earnings History > 1 > date
2025-03-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.15
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-0.15
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2023-03-31
Earnings History > 2 > report Date
2023-04-20
Earnings History > 2 > date
2023-03-31
Earnings History > 2 > before After Market
BeforeMarket
Earnings History > 2 > currency
GBP
Earnings History > 2 > eps Actual
-0.16
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2022-06-30
Earnings History > 3 > report Date
2022-09-08
Earnings History > 3 > date
2022-06-30
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
GBP
Earnings History > 3 > eps Actual
-0.16
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
-0.16
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2022-03-31
Earnings History > 4 > report Date
2022-04-25
Earnings History > 4 > date
2022-03-31
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
GBP
Earnings History > 4 > eps Actual
-0.17
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
-0.17
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2021-06-30
Earnings History > 5 > report Date
2021-09-23
Earnings History > 5 > date
2021-06-30
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
GBP
Earnings History > 5 > eps Actual
-0.06
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
-0.06
Earnings History > 5 > surprise Percent
-
Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes; and specialty hospital products. In addition, the company is developing AT247, an ultra-rapid acting insulin, which is in Phase 1 for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product; and Medtronic plc to develop a novel thermostable insulin for implantable pump delivery. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Stock Price
GBp 0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AIs London Stock Exchange Group a Buy After Share Price Slump? Morningstar Canada
Read more →The London Stock Exchange is on a long and sad path to oblivion The Telegraph
Read more →Showing 2 of 10
(Last Updated 2025-06-30)
Rating:
BUY
$
Analyst Picks
Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Arecor Therapeutics PLC
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-06-30
EPS Actual
-0.07
EPS Estimate
0
EPS Difference
-0.07
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
£ 0
Cost Of Revenue
£ 0
Gross Profit
£ 0
Operating Expenses
£ 0
Operating Income
£ 0
Interest Expense
£ 0
Pretax Income
£ 0
Net Income
£ 0
Income Tax Expense
£ 0
EBITDA
£ 0
Total Other Income Expense Net
£ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
£ 0
Short Term Investments
£ 0
Receivables
£ 0
Inventories
£ 0
Total Current Assets
£ 0
Property Plant Equipment
£ 0
Total Assets
£ 0
Payables
£ 0
Short Term Debt
£ 0
Long Term Debt
£ 0
Total Liabilities
£ 0
Equity
£ 0
(Last Updated 2025-06-30)
Net Income
£ 0
Depreciation
£ 0
Change In Working Capital
£ 0
Cash From Operations
£ 0
Capital Expenditures
£ 0
Cash From Investing
£ 0
Cash From Financing
£ 0
Net Change In Cash
£ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.